Meilan K Han

List of Publications by Citations

249 papers	12,694 citations	53 h-index	108 g-index
276 ext. papers	16,252 ext. citations	8.7 avg, IF	6.05 L-index

#	Paper	IF	Citations
249	Azithromycin for prevention of exacerbations of COPD. *New England Journal of Medicine*, **2011**, 365, 689-98	59.2	812
248	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. *European Respiratory Journal*, **2019**, 53,	13.6	722
247	Chronic obstructive pulmonary disease phenotypes: the future of COPD. *American Journal of Respiratory and Critical Care Medicine*, **2010**, 182, 598-604	10.2	678
246	Analysis of the lung microbiome in the "healthy" smoker and in COPD. *PLoS ONE*, **2011**, 6, e16384	3.7	614
245	Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. *Nature Medicine*, **2012**, 18, 1711-5	50.5	463
244	Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function. *New England Journal of Medicine*, **2016**, 374, 1811-21	59.2	355
243	Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. *Lancet Respiratory Medicine,the*, **2013**, 1, 309-317	35.1	341
242	Pulmonary arterial enlargement and acute exacerbations of COPD. *New England Journal of Medicine*, **2012**, 367, 913-21	59.2	316
241	Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. *Radiology*, **2011**, 261, 274-82	20.5	300
240	Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. *Lancet Respiratory Medicine,the*, **2014**, 2, 548-56	35.1	252
239	Sex differences in severe pulmonary emphysema. *American Journal of Respiratory and Critical Care Medicine*, **2007**, 176, 243-52	10.2	249
238	Clinical and Radiologic Disease in Smokers With Normal Spirometry. *JAMA Internal Medicine*, **2015**, 175, 1539-49	11.5	243
237	The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. *Chest*, **2011**, 140, 626-633	7.3	229
236	Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS). *Thorax*, **2014**, 69, 491-4	7.3	212
235	Association between Functional Small Airway Disease and FEV1 Decline in Chronic Obstructive Pulmonary Disease. *American Journal of Respiratory and Critical Care Medicine*, **2016**, 194, 178-84	10.2	194
234	Airway Mucin Concentration as a Marker of Chronic Bronchitis. *New England Journal of Medicine*, **2017**, 377, 911-922	59.2	182
233	GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. *Lancet Respiratory Medicine,the*, **2013**, 1, 43-50	35.1	171

232	Significance of the microbiome in obstructive lung disease. *Thorax*, **2012**, 67, 456-63	7.3	161
231	Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. *Chest*, **2013**, 143, 1699-1708	5.3	149
230	Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. *Lancet Respiratory Medicine,the*, **2017**, 5, 619-626	35.1	148
229	Pulmonary diseases and the heart. *Circulation*, **2007**, 116, 2992-3005	16.7	146
228	Spirometry utilization for COPD: how do we measure up?. *Chest*, **2007**, 132, 403-9	5.3	144
227	Computed tomographic measures of pulmonary vascular morphology in smokers and their clinical implications. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 188, 231-9	10.2	142
226	Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. *Lancet Respiratory Medicine,the*, **2017**, 5, 956-967	35.1	140
225	SPIROMICS Protocol for Multicenter Quantitative Computed Tomography to Phenotype the Lungs. *American Journal of Respiratory and Critical Care Medicine*, **2016**, 194, 794-806	10.2	132
224	MMP mediated degradation of type IV collagen alpha 1 and alpha 3 chains reflects basement membrane remodeling in experimental and clinical fibrosis--validation of two novel biomarker assays. *PLoS ONE*, **2013**, 8, e84934	3.7	110
223	Epidemiology, genetics, and subtyping of preserved ratio impaired spirometry (PRISm) in COPDGene. *Respiratory Research*, **2014**, 15, 89	7.3	109
222	Lung Microbiota Contribute to Pulmonary Inflammation and Disease Progression in Pulmonary Fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 199, 1127-1138	10.2	103
221	Quantitative computed tomography of the lungs and airways in healthy nonsmoking adults. *Investigative Radiology*, **2012**, 47, 596-602	10.1	99
220	Relationship between quantitative CT metrics and health status and BODE in chronic obstructive pulmonary disease. *Thorax*, **2012**, 67, 399-406	7.3	97
219	At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 197, 1540-1551	10.2	94
218	Cluster analysis in the COPDGene study identifies subtypes of smokers with distinct patterns of airway disease and emphysema. *Thorax*, **2014**, 69, 415-22	7.3	94
217	Microbes Are Associated with Host Innate Immune Response in Idiopathic Pulmonary Fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 196, 208-219	10.2	89
216	Comparison of spatially matched airways reveals thinner airway walls in COPD. The Multi-Ethnic Study of Atherosclerosis (MESA) COPD Study and the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS). *Thorax*, **2014**, 69, 987-96	7.3	86
215	Undiagnosed Obstructive Lung Disease in the United States. Associated Factors and Long-term Mortality. *Annals of the American Thoracic Society*, **2015**, 12, 1788-95	4.7	85

214	Women and Lung Disease. Sex Differences and Global Health Disparities. *American Journal of Respiratory and Critical Care Medicine*, **2015**, 192, 11-6	10.2	80
213	CT-based Visual Classification of Emphysema: Association with Mortality in the COPDGene Study. *Radiology*, **2018**, 288, 859-866	20.5	80
212	Clinical significance of radiologic characterizations in COPD. *COPD: Journal of Chronic Obstructive Pulmonary Disease*, **2009**, 6, 459-67	2	75
211	Biomarkers Predictive of Exacerbations in the SPIROMICS and COPDGene Cohorts. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 195, 473-481	10.2	73
210	Paired inspiratory-expiratory chest CT scans to assess for small airways disease in COPD. *Respiratory Research*, **2013**, 14, 42	7.3	73
209	Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine*, **2009**, 180, 499-505	10.2	68
208	Parametric response mapping monitors temporal changes on lung CT scans in the subpopulations and intermediate outcome measures in COPD Study (SPIROMICS). *Academic Radiology*, **2015**, 22, 186-94	4.3	67
207	Clinical and computed tomographic predictors of chronic bronchitis in COPD: a cross sectional analysis of the COPDGene study. *Respiratory Research*, **2014**, 15, 52	7.3	66
206	The Role of Chest Computed Tomography in the Evaluation and Management of the Patient with Chronic Obstructive Pulmonary Disease. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 196, 1372-1379	10.2	65
205	Common Genetic Polymorphisms Influence Blood Biomarker Measurements in COPD. *PLoS Genetics* , **2016**, 12, e1006011	6	64
204	Noninvasive Imaging Biomarker Identifies Small Airway Damage in Severe Chronic Obstructive Pulmonary Disease. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 200, 575-581	10.2	62
203	A New Approach for Identifying Patients with Undiagnosed Chronic Obstructive Pulmonary Disease. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 195, 748-756	10.2	62
202	Prediction of acute respiratory disease in current and former smokers with and without COPD. *Chest*, **2014**, 146, 941-950	5.3	61
201	COPDGene 2019: Redefining the Diagnosis of Chronic Obstructive Pulmonary Disease. *Chronic Obstructive Pulmonary Diseases (Miami, Fla)*, **2019**, 6, 384-399	2.7	61
200	Improving the Management of COPD in Women. *Chest*, **2017**, 151, 686-696	5.3	60
199	Longitudinal Phenotypes and Mortality in Preserved Ratio Impaired Spirometry in the COPDGene Study. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 198, 1397-1405	10.2	59
198	Meeting the challenge of COPD care delivery in the USA: a multiprovider perspective. *Lancet Respiratory Medicine,the*, **2016**, 4, 473-526	35.1	57
197	Human airway branch variation and chronic obstructive pulmonary disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E974-E981	11.5	53

196	Lung CD8+ T cells in COPD have increased expression of bacterial TLRs. *Respiratory Research*, **2013**, 14, 13	7.3	53
195	The clinical impact of non-obstructive chronic bronchitis in current and former smokers. *Respiratory Medicine*, **2014**, 108, 491-9	4.6	52
194	Metoprolol for the Prevention of Acute Exacerbations of COPD. *New England Journal of Medicine*, **2019**, 381, 2304-2314	59.2	51
193	Impact of self-reported gastroesophageal reflux disease in subjects from COPDGene cohort. *Respiratory Research*, **2014**, 15, 62	7.3	51
192	An airway epithelial IL-17A response signature identifies a steroid-unresponsive COPD patient subgroup. *Journal of Clinical Investigation*, **2019**, 129, 169-181	15.9	50
191	Electronic Cigarette Use in US Adults at Risk for or with COPD: Analysis from Two Observational Cohorts. *Journal of General Internal Medicine*, **2017**, 32, 1315-1322	4	48
190	The association of plasma biomarkers with computed tomography-assessed emphysema phenotypes. *Respiratory Research*, **2014**, 15, 127	7.3	48
189	Goals of COPD treatment: Focus on symptoms and exacerbations. *Respiratory Medicine*, **2020**, 166, 105938	4.6	44
188	Female Sex and Gender in Lung/Sleep Health and Disease. Increased Understanding of Basic Biological, Pathophysiological, and Behavioral Mechanisms Leading to Better Health for Female Patients with Lung Disease. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 198, 850-858	10.2	44
187	Age and Small Airway Imaging Abnormalities in Subjects with and without Airflow Obstruction in SPIROMICS. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 195, 464-472	10.2	44
186	A simplified score to quantify comorbidity in COPD. *PLoS ONE*, **2014**, 9, e114438	3.7	44
185	Gender differences in symptoms and care delivery for chronic obstructive pulmonary disease. *Journal of Womenjs Health*, **2012**, 21, 1267-74	3	44
184	Association between airway caliber changes with lung inflation and emphysema assessed by volumetric CT scan in subjects with COPD. *Chest*, **2012**, 141, 736-744	5.3	43
183	Racial differences in quality of life in patients with COPD. *Chest*, **2011**, 140, 1169-1176	5.3	42
182	Chronic obstructive pulmonary disease, cognitive impairment, and development of disability: the health and retirement study. *Annals of the American Thoracic Society*, **2014**, 11, 1362-70	4.7	40
181	Understanding the role of the microbiome in chronic obstructive pulmonary disease: principles, challenges, and future directions. *Translational Research*, **2017**, 179, 71-83	11	39
180	Non-emphysematous chronic obstructive pulmonary disease is associated with diabetes mellitus. *BMC Pulmonary Medicine*, **2014**, 14, 164	3.5	39
179	Arterial Vascular Pruning, Right Ventricular Size, and Clinical Outcomes in Chronic Obstructive Pulmonary Disease. A Longitudinal Observational Study. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 200, 454-461	10.2	37

178	Sex-specific features of emphysema among current and former smokers with COPD. *European Respiratory Journal*, **2016**, 47, 104-12	13.6	37
177	Acute exacerbations of chronic obstructive pulmonary disease are associated with decreased CD4+ & CD8+ T cells and increased growth & differentiation factor-15 (GDF-15) in peripheral blood. *Respiratory Research*, **2015**, 16, 94	7.3	37
176	Human CD56+ cytotoxic lung lymphocytes kill autologous lung cells in chronic obstructive pulmonary disease. *PLoS ONE*, **2014**, 9, e103840	3.7	36
175	A simple algorithm for the identification of clinical COPD phenotypes. *European Respiratory Journal* , **2017**, 50,	13.6	35
174	Association of Dysanapsis With Chronic Obstructive Pulmonary Disease Among Older Adults. *JAMA - Journal of the American Medical Association*, **2020**, 323, 2268-2280	27.4	34
173	Inflammatory leukocyte phenotypes correlate with disease progression in idiopathic pulmonary fibrosis. *Frontiers in Medicine*, **2014**, 1,	4.9	34
172	Comorbidities of COPD have a major impact on clinical outcomes, particularly in African Americans. *Chronic Obstructive Pulmonary Diseases (Miami, Fla)*, **2014**, 1, 105-114	2.7	32
171	Handgrip Strength in Chronic Obstructive Pulmonary Disease. Associations with Acute Exacerbations and Body Composition. *Annals of the American Thoracic Society*, **2017**, 14, 1638-1645	4.7	31
170	Microbiome in interstitial lung disease: from pathogenesis to treatment target. *Current Opinion in Pulmonary Medicine*, **2017**, 23, 404-410	3	30
169	Contribution of the environment and comorbidities to chronic obstructive pulmonary disease phenotypes. *Medical Clinics of North America*, **2012**, 96, 713-27	7	30
168	Gender influences Health-Related Quality of Life in IPF. *Respiratory Medicine*, **2010**, 104, 724-30	4.6	30
167	Voxel-Wise Longitudinal Parametric Response Mapping Analysis of Chest Computed Tomography in Smokers. *Academic Radiology*, **2019**, 26, 217-223	4.3	29
166	Clinical Epidemiology of COPD: Insights From 10 Years of the COPDGene Study. *Chest*, **2019**, 156, 228-238	9.3	29
165	Role of infection and antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease. *Expert Review of Anti-Infective Therapy*, **2006**, 4, 101-24	5.5	29
164	Diffusing Capacity of Carbon Monoxide in Assessment of COPD. *Chest*, **2019**, 156, 1111-1119	5.3	28
163	Chronic respiratory diseases: a global view. *Lancet Respiratory Medicine,the*, **2020**, 8, 531-533	35.1	28
162	Racial differences in CT phenotypes in COPD. *COPD: Journal of Chronic Obstructive Pulmonary Disease*, **2013**, 10, 20-7	2	27
161	Chronic Respiratory Symptoms with Normal Spirometry. A Reliable Clinical Entity?. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 195, 17-22	10.2	27

160	Identifying Patients with Undiagnosed COPD in Primary Care Settings: Insight from Screening Tools and Epidemiologic Studies. *Chronic Obstructive Pulmonary Diseases (Miami, Fla)*, **2015**, 2, 103-121	2.7	27
159	Biomechanical CT metrics are associated with patient outcomes in COPD. *Thorax*, **2017**, 72, 409-414	7.3	26
158	COPD Care in the 21st Century: A Public Health Priority. *Respiratory Care*, **2018**, 63, 591-600	2.1	26
157	Clinical Approach to the Therapy of Asthma-COPD Overlap. *Chest*, **2019**, 155, 168-177	5.3	26
156	From GOLD 0 to Pre-COPD. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 203, 414-423	10.2	26
155	Randomised clinical trial to determine the safety of quercetin supplementation in patients with chronic obstructive pulmonary disease. *BMJ Open Respiratory Research*, **2020**, 7,	5.6	25
154	Age-Related Differences in Health-Related Quality of Life in COPD: An Analysis of the COPDGene and SPIROMICS Cohorts. *Chest*, **2016**, 149, 927-35	5.3	25
153	Five-year Progression of Emphysema and Air Trapping at CT in Smokers with and Those without Chronic Obstructive Pulmonary Disease: Results from the COPDGene Study. *Radiology*, **2020**, 295, 218-226	29.5	24
152	Association of Long-term Ambient Ozone Exposure With Respiratory Morbidity in Smokers. *JAMA Internal Medicine*, **2020**, 180, 106-115	11.5	24
151	Serum IgG and risk of exacerbations and hospitalizations in chronic obstructive pulmonary disease. *Journal of Allergy and Clinical Immunology*, **2017**, 140, 1164-1167.e6	11.5	22
150	A Genetic Risk Score Associated with Chronic Obstructive Pulmonary Disease Susceptibility and Lung Structure on Computed Tomography. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 200, 721-731	10.2	22
149	Relationship between lung function impairment and health-related quality of life in COPD and interstitial lung disease. *Chest*, **2012**, 142, 704-711	5.3	22
148	Mortality and Exacerbations by Global Initiative for Chronic Obstructive Lung Disease Groups ABCD: 2011 Versus 2017 in the COPDGene Cohort. *Chronic Obstructive Pulmonary Diseases (Miami, Fla)*, **2019**, 6, 64-73	2.7	22
147	Respiratory Symptoms Items from the COPD Assessment Test Identify Ever-Smokers with Preserved Lung Function at Higher Risk for Poor Respiratory Outcomes. An Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort. *Annals of the American Thoracic Society*, **2017**, 14, 636-642	4.7	21
146	Effect of emphysema on CT scan measures of airway dimensions in smokers. *Chest*, **2013**, 143, 687-693	5.3	21
145	Serum IgG subclass levels and risk of exacerbations and hospitalizations in patients with COPD. *Respiratory Research*, **2018**, 19, 30	7.3	20
144	Internet access and use by COPD patients in the National Emphysema/COPD Association Survey. *BMC Pulmonary Medicine*, **2014**, 14, 66	3.5	20
143	Differentiation of quantitative CT imaging phenotypes in asthma versus COPD. *BMJ Open Respiratory Research*, **2017**, 4, e000252	5.6	20

142	Disease Progression Modeling in Chronic Obstructive Pulmonary Disease. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 201, 294-302	10.2	20
141	Airway mucin MUC5AC and MUC5B concentrations and the initiation and progression of chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. *Lancet Respiratory Medicine,the*, **2021**, 9, 1241-1254	35.1	20
140	Chronic Obstructive Pulmonary Disease in America© Black Population. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 200, 423-430	10.2	19
139	Elevated circulating MMP-9 is linked to increased COPD exacerbation risk in SPIROMICS and COPDGene. *JCI Insight*, **2018**, 3,	9.9	19
138	Association of urine mitochondrial DNA with clinical measures of COPD in the SPIROMICS cohort. *JCI Insight*, **2020**, 5,	9.9	19
137	Airway fractal dimension predicts respiratory morbidity and mortality in COPD. *Journal of Clinical Investigation*, **2018**, 128, 5374-5382	15.9	19
136	The 2017 Update to the COPD Foundation COPD Pocket Consultant Guide. *Chronic Obstructive Pulmonary Diseases (Miami, Fla)*, **2017**, 4, 177-185	2.7	19
135	Alignment of Inhaled Chronic Obstructive Pulmonary Disease Therapies with Published Strategies. Analysis of the Global Initiative for Chronic Obstructive Lung Disease Recommendations in SPIROMICS. *Annals of the American Thoracic Society*, **2019**, 16, 200-208	4.7	19
134	Update in chronic obstructive pulmonary disease in 2010. *American Journal of Respiratory and Critical Care Medicine*, **2011**, 183, 1311-5	10.2	18
133	Defining Impaired Respiratory Health. A Paradigm Shift for Pulmonary Medicine. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 198, 440-446	10.2	17
132	Basal gene expression by lung CD4+ T cells in chronic obstructive pulmonary disease identifies independent molecular correlates of airflow obstruction and emphysema extent. *PLoS ONE*, **2014**, 9, e96421	3.7	17
131	Clinical correlations of computed tomography imaging in chronic obstructive pulmonary disease. *Annals of the American Thoracic Society*, **2013**, 10 Suppl, S131-7	4.7	17
130	The Effects of Rare Variants on Lung Function and Emphysema in SPIROMICS. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 201, 540-554	10.2	17
129	CT-derived Biomechanical Metrics Improve Agreement Between Spirometry and Emphysema. *Academic Radiology*, **2016**, 23, 1255-63	4.3	17
128	Rural Residence and Chronic Obstructive Pulmonary Disease Exacerbations. Analysis of the SPIROMICS Cohort. *Annals of the American Thoracic Society*, **2018**, 15, 808-816	4.7	16
127	Anemia and Adverse Outcomes in a Chronic Obstructive Pulmonary Disease Population with a High Burden of Comorbidities. An Analysis from SPIROMICS. *Annals of the American Thoracic Society*, **2018**, 15, 710-717	4.7	16
126	GDF-15 plasma levels in chronic obstructive pulmonary disease are associated with subclinical coronary artery disease. *Respiratory Research*, **2017**, 18, 42	7.3	15
125	Design of the Subpopulations and Intermediate Outcome Measures in COPD (SPIROMICS) AIR Study. *BMJ Open Respiratory Research*, **2017**, 4, e000186	5.6	15

124	Machine Learning and Prediction of All-Cause Mortality in COPD. *Chest*, **2020**, 158, 952-964	5.3	15
123	Association between Emphysema and Chronic Obstructive Pulmonary Disease Outcomes in the COPDGene and SPIROMICS Cohorts: A Post Hoc Analysis of Two Clinical Trials. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 198, 265-267	10.2	15
122	Relationship of Absolute Telomere Length With Quality of Life, Exacerbations, and Mortality in COPD. *Chest*, **2018**, 154, 266-273	5.3	15
121	The Impact of Sources of Variability on Parametric Response Mapping of Lung CT Scans. *Tomography*, **2015**, 1, 69-77	3.1	15
120	Pharmacotherapeutic approaches to preventing acute exacerbations of chronic obstructive pulmonary disease. *Proceedings of the American Thoracic Society*, **2011**, 8, 356-62		15
119	Association of thrombocytosis with COPD morbidity: the SPIROMICS and COPDGene cohorts. *Respiratory Research*, **2018**, 19, 20	7.3	14
118	Lower serum IgA is associated with COPD exacerbation risk in SPIROMICS. *PLoS ONE*, **2018**, 13, e0194924	3.7	14
117	Socioeconomic Characteristics Are Major Contributors to Ethnic Differences in Health Status in Obstructive Lung Disease: An Analysis of the National Health and Nutrition Examination Survey 2007-2010. *Chest*, **2015**, 148, 151-158	5.3	14
116	Comprehensive stereological assessment of the human lung using multiresolution computed tomography. *Journal of Applied Physiology*, **2020**, 128, 1604-1616	3.7	14
115	A digital protein microarray for COVID-19 cytokine storm monitoring. *Lab on A Chip*, **2021**, 21, 331-343	7.2	14
114	Risk factors for COPD exacerbations in inhaled medication users: the COPDGene study biannual longitudinal follow-up prospective cohort. *BMC Pulmonary Medicine*, **2016**, 16, 28	3.5	13
113	Radiographic lung volumes predict progression to COPD in smokers with preserved spirometry in SPIROMICS. *European Respiratory Journal*, **2019**, 54,	13.6	13
112	Mucus Plugs and Emphysema in the Pathophysiology of Airflow Obstruction and Hypoxemia in Smokers. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 203, 957-968	10.2	13
111	Improving Detection of Early Chronic Obstructive Pulmonary Disease. *Annals of the American Thoracic Society*, **2018**, 15, S243-S248	4.7	13
110	Occupational Exposures and Computed Tomographic Imaging Characteristics in the SPIROMICS Cohort. *Annals of the American Thoracic Society*, **2018**, 15, 1411-1419	4.7	13
109	Aspirin Use and Respiratory Morbidity in COPD: A Propensity Score-Matched Analysis in Subpopulations and Intermediate Outcome Measures in COPD Study. *Chest*, **2019**, 155, 519-527	5.3	11
108	Chronic Obstructive Pulmonary Disease in Women: A Biologically Focused Review with a Systematic Search Strategy. *International Journal of COPD*, **2020**, 15, 711-721	3	11
107	Practical Considerations for the Diagnosis and Management of Asthma in Older Adults. *Mayo Clinic Proceedings*, **2017**, 92, 1697-1705	6.4	11

106	Variability in objective and subjective measures affects baseline values in studies of patients with COPD. *PLoS ONE*, **2017**, 12, e0184606	3.7	11
105	Heterogeneous burden of lung disease in smokers with borderline airflow obstruction. *Respiratory Research*, **2018**, 19, 223	7.3	11
104	Lung Mass in Smokers. *Academic Radiology*, **2017**, 24, 386-392	4.3	10
103	Older adults with chronic lung disease report less limitation compared with younger adults with similar lung function impairment. *Annals of the American Thoracic Society*, **2015**, 12, 21-6	4.7	10
102	Artificial Intelligence and Chest Imaging. Will Deep Learning Make Us Smarter?. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 197, 148-150	10.2	10
101	Serum amino acid concentrations and clinical outcomes in smokers: SPIROMICS metabolomics study. *Scientific Reports*, **2019**, 9, 11367	4.9	10
100	Increased airway iron parameters and risk for exacerbation in COPD: an analysis from SPIROMICS. *Scientific Reports*, **2020**, 10, 10562	4.9	10
99	Understanding the impact of second-hand smoke exposure on clinical outcomes in participants with COPD in the SPIROMICS cohort. *Thorax*, **2016**, 71, 411-420	7.3	10
98	Contribution of Individual and Neighborhood Factors to Racial Disparities in Respiratory Outcomes. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 203, 987-997	10.2	10
97	Centrilobular emphysema and coronary artery calcification: mediation analysis in the SPIROMICS cohort. *Respiratory Research*, **2018**, 19, 257	7.3	10
96	New Spirometry Indices for Detecting Mild Airflow Obstruction. *Scientific Reports*, **2018**, 8, 17484	4.9	10
95	Disruption of histidine and energy homeostasis in chronic obstructive pulmonary disease. *International Journal of COPD*, **2019**, 14, 2015-2025	3	9
94	Systemic Markers of Inflammation in Smokers With Symptoms Despite Preserved Spirometry in SPIROMICS. *Chest*, **2019**, 155, 908-917	5.3	9
93	Pulmonary artery enlargement and mortality risk in moderate to severe COPD: results from COPDGene. *European Respiratory Journal*, **2020**, 55,	13.6	9
92	NT-proBNP in stable COPD and future exacerbation risk: Analysis of the SPIROMICS cohort. *Respiratory Medicine*, **2018**, 140, 87-93	4.6	9
91	Insight into Best Variables for COPD Case Identification: A Random Forests Analysis. *Chronic Obstructive Pulmonary Diseases (Miami, Fla)*, **2016**, 3, 406-418	2.7	9
90	Lung microbiota associations with clinical features of COPD in the SPIROMICS cohort. *Npj Biofilms and Microbiomes*, **2021**, 7, 14	8.2	9
89	Reprint of: Voxel-Wise Longitudinal Parametric Response Mapping Analysis of Chest Computed Tomography in Smokers. *Academic Radiology*, **2019**, 26, 306-312	4.3	8

88	Structural and Functional Features on Quantitative Chest Computed Tomography in the Korean Asian versus the White American Healthy Non-Smokers. *Korean Journal of Radiology*, **2019**, 20, 1236-1245	6.9	8
87	Clinical Phenotypes of Atopy and Asthma in COPD: A Meta-analysis of SPIROMICS and COPDGene. *Chest*, **2020**, 158, 2333-2345	5.3	8
86	Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee. *Annals of the American Thoracic Society*, **2019**, 16, 29-39	4.7	8
85	Safety and Tolerability of Comprehensive Research Bronchoscopy in Chronic Obstructive Pulmonary Disease. Results from the SPIROMICS Bronchoscopy Substudy. *Annals of the American Thoracic Society*, **2019**, 16, 439-446	4.7	8
84	Serum IgG Levels and Risk of COPD Hospitalization: A Pooled Meta-analysis. *Chest*, **2020**, 158, 1420-1430	5.3	7
83	Association between acute respiratory disease events and the promoter polymorphism in smokers. *Thorax*, **2018**, 73, 1071-1074	7.3	7
82	COPD in 2016: some answers, more questions. *Lancet Respiratory Medicine,the*, **2016**, 4, 941-943	35.1	7
81	Can CAPTURE be used to identify undiagnosed patients with mild-to-moderate COPD likely to benefit from treatment?. *International Journal of COPD*, **2018**, 13, 1901-1912	3	7
80	Treatment Trials in Young Patients with COPD and Pre-COPD Patients: Time to Move Forward. *American Journal of Respiratory and Critical Care Medicine*, **2021**,	10.2	7
79	Adult Life-Course Trajectories of Lung Function and the Development of Emphysema: The CARDIA Lung Study. *American Journal of Medicine*, **2020**, 133, 222-230.e11	2.4	7
78	Quantitative Emphysema on Low-Dose CT Imaging of the Chest and Risk of Lung Cancer and Airflow Obstruction: An Analysis of the National Lung Screening Trial. *Chest*, **2021**, 159, 1812-1820	5.3	7
77	Seven Pillars of Small Airways Disease in Asthma and COPD: Supporting Opportunities for Novel Therapies. *Chest*, **2021**, 160, 114-134	5.3	7
76	The Peak Index: Spirometry Metric for Airflow Obstruction Severity and Heterogeneity. *Annals of the American Thoracic Society*, **2019**, 16, 982-989	4.7	6
75	DNA Methylation Is Predictive of Mortality in Current and Former Smokers. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 201, 1099-1109	10.2	6
74	The Association Between Neighborhood Socioeconomic Disadvantage and Chronic Obstructive Pulmonary Disease. *International Journal of COPD*, **2020**, 15, 981-993	3	6
73	Identifying Smoking-Related Disease on Lung Cancer Screening CT Scans: Increasing the Value. *Chronic Obstructive Pulmonary Diseases (Miami, Fla)*, **2019**, 6, 233-245	2.7	6
72	Genetic and non-genetic factors affecting the expression of COVID-19-relevant genes in the large airway epithelium. *Genome Medicine*, **2021**, 13, 66	14.4	6
71	A controlled statistical study to assess measurement variability as a function of test object position and configuration for automated surveillance in a multicenter longitudinal COPD study (SPIROMICS). *Medical Physics*, **2016**, 43, 2598	4.4	6

70	Informing Healthcare Decisions with Observational Research Assessing Causal Effect. An Official American Thoracic Society Research Statement. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 203, 14-23	10.2	6
69	Protocol Summary of the COPD Assessment in Primary Care To Identify Undiagnosed Respiratory Disease and Exacerbation Risk (CAPTURE) Validation in Primary Care Study. *Chronic Obstructive Pulmonary Diseases (Miami, Fla)*, **2021**, 8,	2.7	6
68	Antibiotics for COPD exacerbations. *Lancet Respiratory Medicine,the*, **2017**, 5, 461-462	35.1	5
67	Differences between absolute and predicted values of forced expiratory volumes to classify ventilatory impairment in chronic obstructive pulmonary disease. *Respiratory Medicine*, **2016**, 111, 30-8	4.6	5
66	Update in chronic obstructive pulmonary disease 2012. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 188, 29-34	10.2	5
65	Identification of Sputum Biomarkers Predictive of Pulmonary Exacerbations in Chronic Obstructive Pulmonary Disease. *Chest*, **2021**,	5.3	5
64	Advances in Chronic Obstructive Pulmonary Disease. *Annual Review of Medicine*, **2021**, 72, 119-134	17.4	5
63	Respiratory exacerbations are associated with muscle loss in current and former smokers. *Thorax*, **2021**, 76, 554-560	7.3	5
62	Effect of daily azithromycin therapy and adherence on readmission risk in COPD. *European Respiratory Journal*, **2019**, 53,	13.6	4
61	External Validation and Recalculation of the CODEX Index in COPD Patients. A 3CIAplus Cohort Study. *COPD: Journal of Chronic Obstructive Pulmonary Disease*, **2019**, 16, 8-17	2	4
60	Smaller Left Ventricle Size at Noncontrast CT Is Associated with Lower Mortality in COPDGene Participants. *Radiology*, **2020**, 296, 208-215	20.5	4
59	GOLD COPD categories are not fit for purpose in primary care--authorsÕreply. *Lancet Respiratory Medicine,the*, **2013**, 1, e17-8	35.1	4
58	Underutilization of Spirometry for the Diagnosis of COPD: Response. *Chest*, **2008**, 133, 314	5.3	4
57	Paired CT Measures of Emphysema and Small Airways Disease and Lung Function and Exercise Capacity in Smokers with Radiographic Bronchiectasis. *Academic Radiology*, **2021**, 28, 370-378	4.3	4
56	Progression of Emphysema and Small Airways Disease in Cigarette Smokers. *Chronic Obstructive Pulmonary Diseases (Miami, Fla)*, **2021**, 8, 198-212	2.7	4
55	Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2015 and GOLD 2019 staging: a pooled analysis of individual patient data. *ERJ Open Research*, **2020**, 6,	3.5	3
54	Azithromycin and risk of COPD exacerbations in patients with and without Helicobacter pylori. *Respiratory Research*, **2017**, 18, 109	7.3	3
53	Reconsidering the Utility of Race-Specific Lung Function Prediction Equations.. *American Journal of Respiratory and Critical Care Medicine*, **2021**,	10.2	3

52	Plasma Cathelicidin is Independently Associated with Reduced Lung Function in COPD: Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort. *Chronic Obstructive Pulmonary Diseases (Miami, Fla)*, **2020**, 7, 370-381	2.7	3
51	Correcting Nonpathological Variation in Longitudinal Parametric Response Maps of CT Scans in COPD Subjects: SPIROMICS. *Tomography*, **2017**, 3, 138-145	3.1	3
50	Introducing the New COPD Pocket Consultant Guide App: Can A Digital Approach Improve Care? A Statement of the COPD Foundation. *Chronic Obstructive Pulmonary Diseases (Miami, Fla)*, **2019**, 6, 210-220	2.7	3
49	Factors influencing decline in quality of life in smokers without airflow obstruction: The COPDGene study. *Respiratory Medicine*, **2020**, 161, 105820	4.6	3
48	Association of plasma mitochondrial DNA with COPD severity and progression in the SPIROMICS cohort. *Respiratory Research*, **2021**, 22, 126	7.3	3
47	Relationship between Emphysema Progression at CT and Mortality in Ever-Smokers: Results from the COPDGene and ECLIPSE Cohorts. *Radiology*, **2021**, 299, 222-231	20.5	3
46	Objectively Measured Chronic Lung Injury on Chest CT. *Chest*, **2019**, 156, 1149-1159	5.3	3
45	Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis. *International Journal of COPD*, **2019**, 14, 2927-2938	3	3
44	Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis. *ERJ Open Research*, **2021**, 7,	3.5	3
43	Confronting the Challenge of COPD: What Is New in the Approaches to Diagnosis, Treatment, and Patient Outcomes. *Chest*, **2018**, 154, 984-985	5.3	3
42	COPD: Clinical Diagnosis and Management **2016**, 767-785.e7		2
41	Inference of Cellular Immune Environments in Sputum and Peripheral Blood Associated with Acute Exacerbations of COPD. *Cellular and Molecular Bioengineering*, **2019**, 12, 165-177	3.9	2
40	Update in Chronic Obstructive Pulmonary Disease 2018. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 199, 1462-1470	10.2	2
39	Impact of bronchiectasis on the frequency and severity of respiratory exacerbations in COPD. *International Journal of COPD*, **2018**, 13, 2335-2338	3	2
38	Developing and Implementing Biomarkers and Novel Imaging in COPD. *Chronic Obstructive Pulmonary Diseases (Miami, Fla)*, **2016**, 3, 485-490	2.7	2
37	Impact of gastroesophageal reflux on longitudinal lung function and quantitative computed tomography in the COPDGene cohort. *Respiratory Research*, **2020**, 21, 203	7.3	2
36	Latent traits of lung tissue patterns in former smokers derived by dual channel deep learning in computed tomography images. *Scientific Reports*, **2021**, 11, 4916	4.9	2
35	GOLD 2019: a new way forward. *Lancet Respiratory Medicine,the*, **2019**, 7, 16-17	35.1	2

34	Modeling residential indoor concentrations of PM , NO , NO , and secondhand smoke in the Subpopulations and Intermediate Outcome Measures in COPD (SPIROMICS) Air study. *Indoor Air*, **2021**, 31, 702-716	5.4	2
33	CT-Based Commercial Software Applications: Improving Patient Care Through Accurate COPD Subtyping.. *International Journal of COPD*, **2022**, 17, 919-930	3	2
32	Longitudinal association between muscle loss and mortality in ever-smokers. *Chest*, **2021**,	5.3	1
31	Chronic obstructive pulmonary disease risk assessment tools: is one better than the others?. *Current Opinion in Pulmonary Medicine*, **2021**, 28,	3	1
30	Novel Respiratory Disability Score Predicts COPD Exacerbations and Mortality in the SPIROMICS Cohort. *International Journal of COPD*, **2020**, 15, 1887-1898	3	1
29	Improved detection of air trapping on expiratory computed tomography using deep learning. *PLoS ONE*, **2021**, 16, e0248902	3.7	1
28	Longitudinal Imaging-Based Clusters in Former Smokers of the COPD Cohort Associate with Clinical Characteristics: The SubPopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). *International Journal of COPD*, **2021**, 16, 1477-1496	3	1
27	Distinguishing Smoking-Related Lung Disease Phenotypes Via Imaging and Molecular Features. *Chest*, **2021**, 159, 549-563	5.3	1
26	Age-Dependent Associations Between 25-Hydroxy Vitamin D Levels and COPD Symptoms: Analysis of SPIROMICS. *Chronic Obstructive Pulmonary Diseases (Miami, Fla)*, **2021**, 8, 277-291	2.7	1
25	Development of the Advancing the Patient Experience in COPD Registry: A Modified Delphi Study. *Chronic Obstructive Pulmonary Diseases (Miami, Fla)*, **2021**, 8,	2.7	1
24	Roflumilast for eosinophilic chronic obstructive pulmonary disease?. *Lancet Respiratory Medicine,the*, **2018**, 6, 802-803	35.1	1
23	Lung Diseases Unique to Women. *Clinics in Chest Medicine*, **2021**, 42, 507-516	5.3	1
22	Ambient ozone effects on respiratory outcomes among smokers modified by neighborhood poverty: An analysis of SPIROMICS AIR.. *Science of the Total Environment*, **2022**, 829, 154694	10.2	1
21	Epigenetic marker of telomeric age is associated with exacerbations and hospitalizations in chronic obstructive pulmonary disease.. *Respiratory Research*, **2021**, 22, 316	7.3	1
20	Host, Gender, and Early-Life Factors as Risks for Chronic Obstructive Pulmonary Disease. *Clinics in Chest Medicine*, **2020**, 41, 329-337	5.3	0
19	Current smoking with or without chronic bronchitis is independently associated with goblet cell hyperplasia in healthy smokers and COPD subjects. *Scientific Reports*, **2020**, 10, 20133	4.9	0
18	Emphysema Progression and Lung Function Decline Among Angiotensin Converting Enzyme Inhibitors and Angiotensin-Receptor Blockade Users in the COPDGene Cohort. *Chest*, **2021**, 160, 1245-1254	5.3	0
17	Defining Resilience to Smoking-related Lung Disease: A Modified Delphi Approach from SPIROMICS. *Annals of the American Thoracic Society*, **2021**, 18, 1822-1831	4.7	0

16	Ratio of FEV/Slow Vital Capacity of Chest, **2021**, 160, 94-103	5.3	0
15	The Association Between Lung Hyperinflation and Coronary Artery Disease in Smokers. *Chest*, **2021**, 160, 858-871	5.3	0
14	The Exacerbation Conundrum. *Archivos De Bronconeumologia*, **2019**, 55, 5-6	0.7	
13	Women and COPD. *Respiratory Medicine*, **2016**, 63-85	0.2	
12	COPD treatment: time to change our algorithm?. *Lancet Respiratory Medicine,the*, **2013**, 1, 176-7	35.1	
11	Parturient Montes. *Radiology*, **2012**, 262, 1042; author reply 1043	20.5	
10	Racial Differences Influence Health-Related Quality-of-Life Measurements: Response. *Chest*, **2012**, 141, 571	5.3	
9	Understanding lung health beliefs in low-resource settings.. *The Lancet Global Health*, **2022**, 10, e6-e7	13.6	
8	X-ray dark field imaging: a tool for early diagnosis of emphysema in chronic obstructive pulmonary disease?. *The Lancet Digital Health*, **2021**, 3, e691-e692	14.4	
7	Phenotypes of COPD **2017**, 147-168		
6	Phosphodiesterase-4 inhibitors for COPD **2012**, 88-102		
5	Reply to Janssen and Wouters: Loss of Alveolar Attachments as a Pathomechanistic Link between Small Airway Disease and Emphysema. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 201, 879-880	10.2	
4	Reply to Thomson, to Neder ., and to Wouters. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 204, 112	10.2	
3	Polycythemia is Associated with Lower Incidence of Severe COPD Exacerbations in the SPIROMICS Study. *Chronic Obstructive Pulmonary Diseases (Miami, Fla)*, **2021**, 8, 326-335	2.7	
2	Letter to Editor Regarding the OCEAN Study [Letter]. *International Journal of COPD*, **2021**, 16, 2501-2502	3	
1	Using Tools as Designed [Letter].. *International Journal of COPD*, **2022**, 17, 591-592	3	